Publications by authors named "I Roca Bielsa"
Article Synopsis
- - A study evaluated the effectiveness and safety of dupilumab for treating bullous pemphigoid in elderly patients, with a focus on those who typically have other health issues that make standard treatments unsuitable.
- - The results showed that 53.4% of patients achieved complete remission within 4 weeks and 95.7% by week 52, with a significant reduction in itchiness and a dramatic decrease in the need for corticosteroids.
- - The treatment was found to be safe, with most adverse events being mild, and factors like shorter disease duration and exclusive skin involvement were linked to better treatment responses.
Background: Chronic spontaneous urticaria (CSU) is a highly prevalent and difficult to manage cutaneous disease characterized by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. One of the biological treatments used for patients with CSU with an autoimmune background and bad control of the disease is omalizumab, an anti-IgE monoclonal antibody. The understanding of the mechanism of action of this biological drug in CSU along with the identification of potential biomarkers of clinical response can be helpful in the personalized management of the disease.
View Article and Find Full Text PDF